Aurinia Pharmaceuticals (AUPH) Invested Capital (2023 - 2026)

Aurinia Pharmaceuticals' Invested Capital history runs 4 years deep, the most recent figure standing at $64.7 million for Q1 2026.

• Quarterly Invested Capital fell 9.3% year-over-year to $64.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281.0 million (down 7.45% YoY) and the FY2025 annual result came in at $68.8 million, down 5.17% from the prior year.
• Invested Capital was $64.7 million for Q1 2026 at Aurinia Pharmaceuticals, down from $68.8 million in the prior quarter.
• Across five years, Invested Capital topped out at $93.4 million in Q2 2023 and bottomed at $64.7 million in Q1 2026.
• A 4-year average of $77.9 million and a median of $77.1 million in 2024 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2024 — Invested Capital decreased 19.42% — and 2025, when it retreated 4.29%.
• Aurinia Pharmaceuticals' Invested Capital stood at $90.1 million in 2023, then dropped by 19.42% to $72.6 million in 2024, then retreated by 5.17% to $68.8 million in 2025, then retreated by 6.02% to $64.7 million in 2026.
• Business Quant data shows AUPH's Invested Capital at $64.7 million in Q1 2026, $68.8 million in Q4 2025, and $72.0 million in Q3 2025.